Amid its recent decision to pump the brakes on the FDA application for its experimental Alzheimer’s drug donanemab, Eli Lilly appears to be casting a wider net in its efforts to improve treatment of the neurodegenerative disease.

Newly snared in that net is Quanterix, which is developing molecular diagnostic tools to detect and analyze disease biomarkers in the blood. Quanterix and Lilly are now joining forces with a primary goal of improving Alzheimer’s diagnoses using Quanterix’s technology and Lilly’s proprietary Alzheimer’s biomarker, plasma-based P-tau217.

Part of their agreement will give Quanterix nonexclusive global access to P-tau217, which it will be able to use first in the creation of new products and services for research use only and, eventually, to develop in vitro diagnostics for Alzheimer’s.

READ THE FULL ARTICLE